Rocket Pharmaceuticals Inc (RCKT)

$3.18 +0.03 (0.95%)
Market Cap 339.90M
Revenue (ttm) 0.00
Net Income (ttm) -258.75M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 2,838,500
Avg Vol 3,724,110
Day's Range N/A - N/A
Shares Out 107.90M
Stochastic %K 18%
Beta 0.60
Analysts Sell
Price Target $8.60

Company Profile

Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases in the United States. It develops vivo adeno-associated viral (AAV) programs, which include programs for Danon disease (DD), a multi-organ lysosomal-associated disorder leading to early death due to heart failure (RP-A501), which is in Phase 2 trial; Plakophilin-2 Arrhythmogenic Cardiomyopathy (PKP2-ACM), an inher...

Industry: Biotechnology
Sector: Healthcare
Phone: 609 659 8001
Address:
9 Cedarbrook Drive, Cranbury, United States
LiquidThetaLEAPS
LiquidThetaLEAPS Oct. 5 at 3:30 AM
LiquidTheta® LEAPS LIVE Actionable Alert Asset: $RCKT Current Share Price: $3.15 Contracts: $RCKT April 17, 2026 $5 Calls Scale in: $0.51- $0.62 Scale out: $0.79-$1.01 Can Easily Capture: 60% ROI Blended DTE: 196 Days | Join Elites here: https://liquidtheta.com/options
0 · Reply
pjapak
pjapak Oct. 4 at 3:05 AM
$RCKT Something is brewing here. They say business strategy so must be better things on horizon.
0 · Reply
geegor
geegor Oct. 3 at 8:38 PM
$RCKT Another director gone. Filed today, days later: https://ir.rocketpharma.com/node/12971/html
1 · Reply
StocktwitsNews
StocktwitsNews Oct. 3 at 5:23 PM
Rocket Pharma Stock Gets A Price Target Cut After Withdrawing FDA Application For Rare Bone Marrow Disorder Gene Therapy $RCKT $IWMW $ESGV https://stocktwits.com/news/equity/markets/rocket-pharma-stock-gets-price-target-cut-after-withdrawing-fda-application-for-rare-bone-marrow-disorder-gene-therapy/chCuqQ5R3Qm
0 · Reply
JarvisFlow
JarvisFlow Oct. 3 at 3:15 PM
Leerink Partners has updated their rating for Rocket Pharmaceuticals ( $RCKT ) to Market Perform with a price target of 7.
0 · Reply
quickaspeter
quickaspeter Oct. 3 at 12:07 PM
$RCKT - The Company’s decision to withdraw the BLA is based on business and strategic considerations and does not reflect concerns regarding the safety or efficacy profile of RP-L102. Data generated to date continue to support that RP-L102 has been generally well tolerated, with no significant safety signals observed, and a risk-benefit profile that appears favorable. - The Company will consider external partnership opportunities that could potentially enable the advancement of RP-L102 in the future. Withdrawal of the BLA preserves Rocket’s ability to re-engage with regulators at a later date should there be an appropriate strategic or partnership pathway to sustainably progress the program.
1 · Reply
JoeBio
JoeBio Oct. 3 at 11:54 AM
$RCKT $IRLANDOTRADER - Here you go...On October 3, 2025, Rocket Pharmaceuticals, Inc. (“Rocket” or the “Company”) reported that it has voluntarily withdrawn its Biologics License Application (“BLA”) to the U.S. Food and Drug Administration (“FDA”) for mozafancogene autotemcel. This decision follows the Company’s previously announced corporate prioritization, under which Rocket is focusing its resources on programs with the clearest regulatory and commercial pathways. The Company will consider external partnership opportunities that could potentially enable the advancement of RP-L102 in the future. Withdrawal of the BLA preserves Rocket’s ability to re-engage with regulators at a later date should there be an appropriate strategic or partnership pathway to sustainably progress the program
1 · Reply
geegor
geegor Oct. 3 at 11:41 AM
$RCKT "...This decision follows the Company’s previously announced corporate prioritization, under which Rocket is focusing its resources on programs with the clearest regulatory and commercial pathways. As a result, Rocket ceased new internal investment in RP-L102 in July 2025, subsequently withdrew its Marketing Authorization Application (“MAA”) with the European Medicines Agency in July 2025, and has now withdrawn its U.S. BLA." https://ir.rocketpharma.com/node/12966/html
0 · Reply
SouthHaus
SouthHaus Oct. 3 at 11:22 AM
$RCKT Rocket Pharmaceuticals said on Friday that it has withdrawn its application for U.S approval of its experimental gene therapy for a rare inherited blood disorder
1 · Reply
Orlandotrader
Orlandotrader Oct. 3 at 12:46 AM
$RCKT Very Quiet here. Some Good News will send this.
0 · Reply
Latest News on RCKT
Rocket Pharmaceuticals withdraws US application of gene therapy for rare blood disorder

Oct 3, 2025, 7:11 AM EDT - 3 days ago

Rocket Pharmaceuticals withdraws US application of gene therapy for rare blood disorder

Rocket Pharmaceuticals, Inc. (RCKT) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Sep 9, 2025, 12:36 PM EDT - 27 days ago

Rocket Pharmaceuticals, Inc. (RCKT) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Rocket Pharmaceuticals to Participate in Upcoming Investor Conferences

Aug 28, 2025, 7:00 AM EDT - 5 weeks ago

Rocket Pharmaceuticals to Participate in Upcoming Investor Conferences

Gene Therapy Trial Can Restart After Patient Death, FDA Says. The Sector Remains Depressed.

Aug 20, 2025, 11:02 AM EDT - 6 weeks ago

Gene Therapy Trial Can Restart After Patient Death, FDA Says. The Sector Remains Depressed.

FDA Lifts Rocket Pharmaceuticals Study Hold For Rare Disease Gene Therapy

Aug 20, 2025, 9:31 AM EDT - 6 weeks ago

FDA Lifts Rocket Pharmaceuticals Study Hold For Rare Disease Gene Therapy

US FDA lifts clinical hold on Rocket Pharmaceuticals' gene therapy trial

Aug 20, 2025, 7:09 AM EDT - 6 weeks ago

US FDA lifts clinical hold on Rocket Pharmaceuticals' gene therapy trial

Rocket Pharmaceuticals Announces FDA Has Lifted the Clinical Hold on the Pivotal Phase 2 Trial of RP-A501 for the Treatment of Danon Disease

Aug 20, 2025, 7:00 AM EDT - 6 weeks ago

Rocket Pharmaceuticals Announces FDA Has Lifted the Clinical Hold on the Pivotal Phase 2 Trial of RP-A501 for the Treatment of Danon Disease

DEADLINE NEXT WEEK: Berger Montague Advises Rocket Pharmaceuticals (NASDAQ: RCKT) Investors to Contact the Firm Before August 11, 2025

Aug 8, 2025, 2:16 PM EDT - 2 months ago

DEADLINE NEXT WEEK: Berger Montague Advises Rocket Pharmaceuticals (NASDAQ: RCKT) Investors to Contact the Firm Before August 11, 2025

Rocket Pharmaceuticals Reports Second Quarter 2025 Financial Results and Highlights Recent Progress

Aug 7, 2025, 4:00 PM EDT - 2 months ago

Rocket Pharmaceuticals Reports Second Quarter 2025 Financial Results and Highlights Recent Progress

SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rocket Pharmaceuticals

Jul 30, 2025, 6:29 PM EDT - 2 months ago

SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rocket Pharmaceuticals

What's Going On With Sarepta, Capricor And Other Gene Therapy Stocks On Wednesday?

Jul 30, 2025, 11:07 AM EDT - 2 months ago

What's Going On With Sarepta, Capricor And Other Gene Therapy Stocks On Wednesday?

CAPR SRPT CABA NGNE NTLA QURE

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rocket Pharmaceuticals

Jul 29, 2025, 10:26 AM EDT - 2 months ago

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rocket Pharmaceuticals

Rocket Refocuses Pipeline As Gene Therapy Sentiment Sours

Jul 25, 2025, 3:02 PM EDT - 2 months ago

Rocket Refocuses Pipeline As Gene Therapy Sentiment Sours

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of August 11, 2025 in Rocket Pharmaceuticals, Inc. Lawsuit – RCKT

Jul 24, 2025, 4:02 PM EDT - 2 months ago

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of August 11, 2025 in Rocket Pharmaceuticals, Inc. Lawsuit – RCKT

Rocket Pharmaceuticals Announces Strategic Corporate Reorganization and Pipeline Prioritization of Cardiovascular Programs

Jul 24, 2025, 7:00 AM EDT - 2 months ago

Rocket Pharmaceuticals Announces Strategic Corporate Reorganization and Pipeline Prioritization of Cardiovascular Programs

Rocket Pharmaceuticals Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for RP-A601 Gene Therapy for PKP2-Arrhythmogenic Cardiomyopathy

Jul 17, 2025, 7:00 AM EDT - 2 months ago

Rocket Pharmaceuticals Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for RP-A601 Gene Therapy for PKP2-Arrhythmogenic Cardiomyopathy

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rocket Pharmaceuticals

Jul 11, 2025, 10:25 AM EDT - 3 months ago

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rocket Pharmaceuticals

Berger Montague PC Investigates Rocket Pharmaceuticals (RCKT) Over Safety Disclosures and Stock Drop

Jul 9, 2025, 5:16 PM EDT - 3 months ago

Berger Montague PC Investigates Rocket Pharmaceuticals (RCKT) Over Safety Disclosures and Stock Drop

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of August 11, 2025 in Rocket Lawsuit - RCKT

Jul 7, 2025, 9:00 AM EDT - 3 months ago

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of August 11, 2025 in Rocket Lawsuit - RCKT

Rocket Pharmaceuticals Announces FDA IND Clearance of RP-A701 for the Treatment of BAG3-associated Dilated Cardiomyopathy

Jun 30, 2025, 7:00 AM EDT - 3 months ago

Rocket Pharmaceuticals Announces FDA IND Clearance of RP-A701 for the Treatment of BAG3-associated Dilated Cardiomyopathy

Rocket Pharmaceuticals, Inc. (RCKT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

Jun 12, 2025, 10:00 AM EDT - 4 months ago

Rocket Pharmaceuticals, Inc. (RCKT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC Encourages Rocket Pharmaceuticals, Inc. (RCKT) Shareholders to Inquire about Securities Investigation

Jun 11, 2025, 10:00 AM EDT - 4 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Rocket Pharmaceuticals, Inc. (RCKT) Shareholders to Inquire about Securities Investigation

LiquidThetaLEAPS
LiquidThetaLEAPS Oct. 5 at 3:30 AM
LiquidTheta® LEAPS LIVE Actionable Alert Asset: $RCKT Current Share Price: $3.15 Contracts: $RCKT April 17, 2026 $5 Calls Scale in: $0.51- $0.62 Scale out: $0.79-$1.01 Can Easily Capture: 60% ROI Blended DTE: 196 Days | Join Elites here: https://liquidtheta.com/options
0 · Reply
pjapak
pjapak Oct. 4 at 3:05 AM
$RCKT Something is brewing here. They say business strategy so must be better things on horizon.
0 · Reply
geegor
geegor Oct. 3 at 8:38 PM
$RCKT Another director gone. Filed today, days later: https://ir.rocketpharma.com/node/12971/html
1 · Reply
StocktwitsNews
StocktwitsNews Oct. 3 at 5:23 PM
Rocket Pharma Stock Gets A Price Target Cut After Withdrawing FDA Application For Rare Bone Marrow Disorder Gene Therapy $RCKT $IWMW $ESGV https://stocktwits.com/news/equity/markets/rocket-pharma-stock-gets-price-target-cut-after-withdrawing-fda-application-for-rare-bone-marrow-disorder-gene-therapy/chCuqQ5R3Qm
0 · Reply
JarvisFlow
JarvisFlow Oct. 3 at 3:15 PM
Leerink Partners has updated their rating for Rocket Pharmaceuticals ( $RCKT ) to Market Perform with a price target of 7.
0 · Reply
quickaspeter
quickaspeter Oct. 3 at 12:07 PM
$RCKT - The Company’s decision to withdraw the BLA is based on business and strategic considerations and does not reflect concerns regarding the safety or efficacy profile of RP-L102. Data generated to date continue to support that RP-L102 has been generally well tolerated, with no significant safety signals observed, and a risk-benefit profile that appears favorable. - The Company will consider external partnership opportunities that could potentially enable the advancement of RP-L102 in the future. Withdrawal of the BLA preserves Rocket’s ability to re-engage with regulators at a later date should there be an appropriate strategic or partnership pathway to sustainably progress the program.
1 · Reply
JoeBio
JoeBio Oct. 3 at 11:54 AM
$RCKT $IRLANDOTRADER - Here you go...On October 3, 2025, Rocket Pharmaceuticals, Inc. (“Rocket” or the “Company”) reported that it has voluntarily withdrawn its Biologics License Application (“BLA”) to the U.S. Food and Drug Administration (“FDA”) for mozafancogene autotemcel. This decision follows the Company’s previously announced corporate prioritization, under which Rocket is focusing its resources on programs with the clearest regulatory and commercial pathways. The Company will consider external partnership opportunities that could potentially enable the advancement of RP-L102 in the future. Withdrawal of the BLA preserves Rocket’s ability to re-engage with regulators at a later date should there be an appropriate strategic or partnership pathway to sustainably progress the program
1 · Reply
geegor
geegor Oct. 3 at 11:41 AM
$RCKT "...This decision follows the Company’s previously announced corporate prioritization, under which Rocket is focusing its resources on programs with the clearest regulatory and commercial pathways. As a result, Rocket ceased new internal investment in RP-L102 in July 2025, subsequently withdrew its Marketing Authorization Application (“MAA”) with the European Medicines Agency in July 2025, and has now withdrawn its U.S. BLA." https://ir.rocketpharma.com/node/12966/html
0 · Reply
SouthHaus
SouthHaus Oct. 3 at 11:22 AM
$RCKT Rocket Pharmaceuticals said on Friday that it has withdrawn its application for U.S approval of its experimental gene therapy for a rare inherited blood disorder
1 · Reply
Orlandotrader
Orlandotrader Oct. 3 at 12:46 AM
$RCKT Very Quiet here. Some Good News will send this.
0 · Reply
boogie_87
boogie_87 Oct. 2 at 4:21 PM
$RCKT your time will come sweet pea just like $TSHA
0 · Reply
Newtimmy
Newtimmy Oct. 2 at 2:20 PM
$RCKT added a few
0 · Reply
Iceman207
Iceman207 Oct. 2 at 6:34 AM
$RCKT
0 · Reply
Orlandotrader
Orlandotrader Oct. 1 at 11:29 PM
$RCKT Same early pump followed by the Dump.
0 · Reply
LiquidThetaLEAPS
LiquidThetaLEAPS Sep. 30 at 9:29 PM
LiquidTheta® LEAPS LIVE Actionable Alert Asset: $RCKT Current Share Price: $3.25 Contracts: $RCKT April 17, 2026 $5 Calls Scale in: $0.65- $0.80 Scale out: $1.02-$1.31 Can Easily Capture: 60% ROI Blended DTE: 200 Days | Join Elites here: https://liquidtheta.com/options
0 · Reply
geegor
geegor Sep. 30 at 3:46 AM
$RCKT New director appointed: Dr Peter Fong, who currently serves as President of RTW Investments LP. Not sure what RTW is up to but if it's their intention to take Rocket private then they had better be willing to pay an appropriate and healthy premium to the current trading range. https://ir.rocketpharma.com/sec-filings/sec-filing/8-k/0001140361-25-036556
2 · Reply
Iceman207
Iceman207 Sep. 30 at 2:47 AM
$RCKT why not
0 · Reply
LiquidThetaLEAPS
LiquidThetaLEAPS Sep. 29 at 6:49 AM
LiquidTheta® LEAPS LIVE Actionable Alert Asset: $RCKT Current Share Price: $3.26 Contracts: $RCKT April 17, 2026 $5 Calls Scale in: $0.64- $0.78 Scale out: $1.00-$1.28 Can Easily Capture: 60% ROI Blended DTE: 201 Days | Join Elites here: https://liquidtheta.com
0 · Reply
LiquidThetaLEAPS
LiquidThetaLEAPS Sep. 27 at 4:03 PM
LiquidTheta® LEAPS LIVE Actionable Alert Asset: $RCKT Current Share Price: $3.21 Contracts: $RCKT April 17, 2026 $5 Calls Scale in: $0.63- $0.77 Scale out: $0.98-$1.26 Can Easily Capture: 60% ROI Blended DTE: 203 Days | Join Elites here: https://liquidtheta.com
0 · Reply
Orlandotrader
Orlandotrader Sep. 27 at 1:28 PM
$RCKT Need to break that 3.50 Level and we should Finally get that Push Higher.
0 · Reply
LiquidThetaLEAPS
LiquidThetaLEAPS Sep. 26 at 5:05 AM
LiquidTheta® LEAPS LIVE Actionable Alert Asset: $RCKT Current Share Price: $3.32 Contracts: $RCKT April 17, 2026 $5 Calls Scale in: $0.62- $0.76 Scale out: $0.96-$1.24 Can Easily Capture: 60% ROI Blended DTE: 204 Days | Join Elites here: https://liquidtheta.com
0 · Reply
soksobay
soksobay Sep. 26 at 3:35 AM
$RCKT cannot do like Qure or Clpt
1 · Reply